Expression of angiogenic markers in jawbones and femur in a rat model treated with zoledronic acid.

Citation metadata

Date: Jan. 10, 2022
From: BMC Research Notes(Vol. 15, Issue 1)
Publisher: BioMed Central Ltd.
Document Type: Article
Length: 2,895 words
Lexile Measure: 1440L

Document controls

Main content

Abstract :

Objectives This study aimed to investigate the gene expression of angiogenic marker in surgically treated jawbones and femur on a rat model administrated with zoledronic acid. Results No soft tissue fenestration or bone exposure was found in femur. Delayed soft tissue healing was found in both ZA group (3 in mandible, 4 in maxilla) and control group (1 in mandible, 2 in maxilla), while exposed bone was found only in the ZA group (1 in maxilla, 2 in mandible). RT-PCR analysis demonstrated no significant difference in gene expression of angiogenetic markers between ZA-treated and control groups in femur and mandible. In the maxilla, the expression of VEGFA and VEGFR-2 in medium-term ZA group was significantly down-regulated compared with that in the control. The ZA treatment does not change significantly the expression of the angiogenic factors in femur and mandible, but significantly downregulates the expression in maxilla in this rat model. The angiogenesis inhibition may contribute to the development of MRONJ but does not play a key role. Keywords: Medication-related osteonecrosis of the jaw, Zoledronic acid, Animal model, Gene expression, Angiogenic markers

Source Citation

Source Citation   

Gale Document Number: GALE|A693697318